Treatment with 2 μM AZA1 also reduced cancer cell migration in all three cell lines when compared to control cells without EGF-stimulation by 40.2 ±12.1% (22Rv1 cells; p<0.01; Figure 4A), 20.2 ±8.9% (DU 145 cells; p<0.04; Figure S4A), and 24.9±16.1% (PC-3 cells; p<0.05; Figure S4A), respectively compared to EGF-stimulated cancer cells. This evidence concerns the gene EGF and cancer.